Precision Partnership: Fireside Chat with GNS Healthcare CEO, Colin Hill and Michael Andreini, CEO of the Multiple Myeloma Research Foundation
During the Personalized Medicine Conference on May 10th and 20, Colin Hill will be participating in a fireside chat with MMRF CEO, Michael Andreini to talk to discuss the significance of cross-sector partnerships to the future of personalized medicine. They will be joined by William S. Dalton, Ph.D., M.D. Founder, Senir Advisor, M2Gen who will […]
Colin Hill to Speak at the 33rd Annual Cancer Progress Conference
The 33rd Annual Cancer Progress Conference, is taking place on May 10th-12th this year. On Tuesday, May 10th, our CEO, Colin Hill, will take part in a panel discussion titled “How to Catch and Treat Cancer Early”. Colin will be joined by Peter Bach, MD, CMO, Delfi Diagnostics; Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC; […]
Meet us at the 9th Drug Discovery Strategic Summit
We are attending the 9th Drug Discovery Strategic Summit in Boston, May 9-10, 2022. Connect with us and let us know if you’d like to schedule a meeting beforehand.
Meet us at Bio-IT World Conference & Expo 2022
Join us at Bio-IT World Conference & Expo, May 3-5, 2022, the world’s premier event showcasing the technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Don’t hesitate to let us know if you’d like to schedule a meeting beforehand.
Colin Hill to Speak at The World Medical Innovation Forum 2022
This year, the World Medical Innovation Forum will explore the promise of new gene and cell therapies, the challenges to their development and investment and market dynamics. The forum features more than 200 CEOs, industry, investment, and government senior leaders from across the Gene and Cell Therapy (GCT) ecosystem. On Tuesday, May 3, Colin Hill, will […]
Meet us at AACR
The AACR Annual Meeting is the focal point of the cancer research community. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Meeting highlights the work of the best minds in cancer research from institutions all over the world. Joe F. Donahue, our Chief Business Officer […]
Colin Hill to Speak at The Longwood Healthcare Leaders Winter Webconference
On Thursday, January 6, Colin Hill, will be moderating a panel on Expediting Research for Treatments and Cures at the Longwood Healthcare Leaders winter webconference. He will be joined by Christopher Coburn, CIO, Mass General Brigham; Ray Deshaies, SVP, Research, Amgen; Raj Devraj, CEO, Rectify Pharma; Brian McVeigh, CEO, Code Biotherapeutics and Chen Schor, Chair, […]
BioCentury highlights GNS-Alexion partnership
Alexion rebuilding pipeline with big data deals August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4 (New York, N.Y.) for genomic sequencing and licensed the Reverse Engineering and Forward Simulation (REFS) […]
FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases
Alexion inks genomics pacts to continue R&D reboot August 11, 2017 – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics. Read the full article here. […]
Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement
Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform August 10, 2017 – Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare’s Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform. Alexion intends to use the platform to accelerate both the research of rare diseases […]